COMPARATIVE STUDY OF AHA-GUIDED INTERVENTIONS FOR MYOCARDIAL INFARCTION FOLLOWED IN A TERTIARY CARE HOSPITAL SETTING IN KHYBER PAKHTUNKHWA, PAKISTAN

Main Article Content

Jawad Azam
Rabia Iqbal
Abdur Rahim
Muhammad Esa
Irfan Hamid
Bashir Ullah
Ahmad Ali
Saira Zahoor
Muhammad Asad
Mujahid Sher
Muhammad Hammad Badshah
Muhammad shafeeq

Keywords

Cardiovascular disease, Myocardial infarction (MI), Pharmacotherapeutic interventions, Standard guidelines of American Health Association (AHA)

Abstract

Background: Cardiovascular disease is the leading cause of mortality worldwide and the incidence increases with advancing age. Myocardial infarction (MI) is a kind of cardiovascular disease in which there is reduced or no supply of oxygenated blood to the heart muscle due to stoppage or blockage in the coronary artery. Major objective of this research was to find out the pharmacotherapeutic interventions and prescription patterns of patients suffering from myocardial infarction are in accordance with the standard guidelines by American Heart Association (AHA/ACC) for the treatment of MI. The study was carried out at cardiology ward Mardan Medical Complex, Khyber Pakhtunkhwa, Pakistan. A total of 130 patients were selected to be included in the study, that were hospitalized and diagnosed with MI.


Results: Results show that MI is more common in male patients (n=87, 66%), with mean age recorded as 51.7±5 years. Highest number of patients were in the age limit of 51-60 (36.25%). Various types of MI were observed during the study, with highest percentage of NSTEMI (31%) followed by IWMI (14%). Various medications were prescribed to the patients, among them enoxaparin (18%), aspirin (17%), streptokinase (12%), clopidogrel (9%) and glyceryl trinitrate (5%) were the top prescribed medications. The MI drugs that were frequently used in the treatment of MI includes anti-platelets, antithrombotic agents, beta blockers, nitroglycerin’s, ACE, and ARBs. Moreover, the most prescribed dosage form was solid dosage form i.e. tablet(s) followed by injectable.


Conclusion: It was found that 80% of the prescriptions were following the guidelines of AHA/ACC for heart patients. More prospective, randomized studies are needed in Pakistan to uncover all problems associated with prescription of MI if AHA guidelines are not followed.

Abstract 63 | PDF Downloads 7

References

1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. Circulation. 2018;138(20):e618-e51.
2. Hartikainen TS, Sörensen NA, Haller PM, Goßling A, Lehmacher J, Zeller T, et al. Clinical application of the 4th Universal Definition of Myocardial Infarction. European heart journal. 2020;41(23):2209-16.
3. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, et al. World Health Organization definition of myocardial infarction: 2008–09 revision. International journal of epidemiology. 2011;40(1):139-46.
4. Tern PJW, Ho AKH, Sultana R, Ahn Y, Almahmeed W, Brieger D, et al. Comparative overview of ST-elevation myocardial infarction epidemiology, demographics, management, and outcomes in five Asia-Pacific countries: a meta-analysis. European Heart Journal-Quality of Care and Clinical Outcomes. 2021;7(1):6-17.
5. Yang, J., Biery, D. W., Singh, A., Divakaran, S., DeFilippis, E. M., Wu, W. Y., ... & Blankstein, R. Risk factors and outcomes of very young adults who experience myocardial infarction: the partners YOUNG-MI registry. The American journal of medicine, 2020; 133(5), 605-612.
6. Hassan K, Mohydin B, Fawwad A, Waris N, Iqbal S, Jawaid M. Predicting the risk of atherosclerotic cardiovascular disease (ASCVD) in Pakistani population. Clinical Epidemiology and Global Health. 2019;7(2):184-7.
7. Iqbal R, Jahan N, Hanif A. Epidemiology and management cost of myocardial infarction in North Punjab, Pakistan. Iranian Red Crescent medical journal. 2015;17(7).
8. Konijnenberg LS, Damman P, Duncker DJ, Kloner RA, Nijveldt R, Van Geuns R-JM, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovascular research. 2020;116(4):787-805.
9. Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018;25(4):277-84.
10. White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal. 2019;40(33):2801-9.
11. Chapman AR, Sandoval Y. Type 2 myocardial infarction: evolving approaches to diagnosis and risk-stratification. Clinical chemistry. 2021;67(1):61-9.
12. Thygesen K, Jaffe AS. Should myocardial infarction type 2 be regarded as two separate entities? European heart journal. 2019;40(33):2810-2.
13. Ferry AV, Anand A, Strachan FE, Mooney L, Stewart SD, Marshall L, et al. Presenting symptoms in men and women diagnosed with myocardial infarction using sex‐specific criteria. Journal of the American Heart Association. 2019;8(17):e012307.
14. Wang, X. Y., Zhang, F., Zhang, C., Zheng, L. R., & Yang, J. The biomarkers for acute myocardial infarction and heart failure. BioMed research international, 2020(1), 2018035.
15. Reddy K, Khaliq A, Henning RJ. Recent advances in the diagnosis and treatment of acute myocardial infarction. World journal of cardiology. 2015;7(5):243.
16. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart. 2006;92(7):987-93.
17. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140(6):e234-e84.
18. Jayaraj JC, Davatyan K, Subramanian S, Priya J. Epidemiology of myocardial infarction. Myocardial Infarction. 2019;10.
19. Ahmadi A, Soori H, Sajjadi H, Nasri H, Mehrabi Y, Etemad K. Current status of the clinical epidemiology of myocardial infarction in men and women: a national cross-sectional study in Iran. International journal of preventive medicine. 2015;6.
20. Rehman S, Li X, Wang C, Ikram M, Rehman E, Liu M. Quality of care for patients with acute myocardial infarction (AMI) in Pakistan: a retrospective study. International journal of environmental research and public health. 2019;16(20):3890.
21. Zahoor S, Mahboob HM, Jehangir HMS, Mehmood B, Khan A, Iqbal U. Frequency of retinal hemorrhage after thrombolysis with streptokinase in patients presenting with ST-elevation myocardial infarction: A single-center experience at a large tertiary care center in Lahore, Pakistan. Journal of Fatima Jinnah Medical University. 2021;15(2):87-90.
22. Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovascular Drugs and Therapy. 2021:1-14.
23. Wu J, Mamas M, Rashid M, Weston C, Hains J, Luescher T, et al. Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic. European Heart Journal-Quality of Care and Clinical Outcomes. 2021;7(3):238-46.
24. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. New England Journal of Medicine. 2012;366(1):54-63.
25. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation. 1994;90(4):2103-14.

Most read articles by the same author(s)